Avoiding overanticoagulation: pharmacogenomics or pragmatism?
Baglin
T
T
D000925:Anticoagulants / Q000008:administration & dosage* / Q000009:adverse effects / Q000493:pharmacokinetics; D001189:Aryl Hydrocarbon Hydroxylases; D003577:Cytochrome P-450 Enzyme System / Q000235:genetics / Q000494:pharmacology; D004347:Drug Interactions; D004351:Drug Resistance; D006470:Hemorrhage / Q000209:etiology; D006801:Humans; D020714:Maximum Tolerated Dose; D010597:Pharmacogenetics; D039181:Steroid 16-alpha-Hydroxylase; D013250:Steroid Hydroxylases / Q000235:genetics / Q000494:pharmacology; D014859:Warfarin / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics
D000925:Anticoagulants; D014859:Warfarin; D003577:Cytochrome P-450 Enzyme System; D013250:Steroid Hydroxylases; D001189:Aryl Hydrocarbon Hydroxylases; D039181:Steroid 16-alpha-Hydroxylase